Sugi Predict

Sugi Predict / Compounds / SCHEMBL8007640

SCHEMBL8007640

SCHEMBL8007640

NCCCCCOOC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DOT1L Q8TEK3 3/20 0.65
▸ DNMT3B Q9UBC3 2/20 0.65
▸ PRMT7 Q9NVM4 1/20 0.65
▸ ADORA1 P30542 3/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.64
▸ ADORA3 P0DMS8 2/20 0.64
▸ ADORA2A P29274 2/20 0.64
▸ ADORA2B P29275 2/20 0.64
▸ DPP4 P27487 1/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ SLC28A1 O00337 1/20 0.64
▸ MAP3K7 O43318 1/20 0.64
▸ SLC28A2 O43868 1/20 0.64
▸ GAPDH P04406 1/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ STAT6 P42226 1/20 0.64
▸ PI4KA P42356 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ PI4K2B Q8TCG2 1/20 0.64
▸ SLC29A1 Q99808 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16094299 0.93 DOT1L (0.62) DOT1LDNMT3BPRMT7ADORA1SMN1; SMN2
SCHEMBL10886673 0.91 DOT1L (0.66) DOT1LDNMT3BPRMT7ADORA1SMN1; SMN2
SCHEMBL6247323 0.89 AHCY (0.71) DOT1LADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL31001584 0.86 P2RY1 (0.61) DOT1LDNMT3BPRMT7ADORA1SMN1; SMN2
SCHEMBL8164443 0.86 P2RY1 (0.68) DOT1LADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL4819105 0.85 P2RY1 (0.70) ADORA1SMN1; SMN2P2RY1SRCP2RY2
SCHEMBL1513014 0.85 P2RY1 (0.77) ADORA1SMN1; SMN2P2RY1SRCP2RY2
SCHEMBL3446755 0.85 ADORA1 (0.71) DOT1LADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL6828798 0.85 ADORA1 (0.70) DOT1LDNMT3BPRMT7ADORA1SMN1; SMN2
SCHEMBL8388991 0.85 DOT1L (0.66) DOT1LDNMT3BPRMT7ADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6022691-A DETECTING A CHEMICAL OR DRUG IN A SAMPLE; CONTACTING THE SAMPLE WITH A NUCLEOTIDE SEQUENCE WHICH HYBRIDIZES TO A SPECIFIC TARGET MOLECULE, DETECTING BINDING OF NUCLEOTIDE SEQUENCES, BINDING IS INDICATION OF DRUG OR CHEMICAL PRESENT ISIS PHARMACEUTICALS, INC. (US) 2000-02-08 — — US disclosed
US-5747253-A Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding ISIS PHARMACEUTICALS, INC. (US) 1998-05-05 — — US disclosed
US-5698391-A DETERMINATION OF TARGET PROPERTY; BIOSYNTHESIS CYCLES ISIS PHARMACEUTICALS, INC. (US) 1997-12-16 — — US disclosed
US-5686242-A Determination of oligonucleotides for therapeutics, diagnostics and research reagents ISIS PHARMACEUTICALS, INC. (US) 1997-11-11 — — US disclosed
US-5672472-A REPEATED ENZYME-FREE SYNTHESIS OF INCREASINGLY SIMPLIFIED SETS OF OLIGONUCLEOTIDES WHILE DETERMINING WHICH SEQUENCE HAS HIGHEST TARGET ACTIVITY ISIS PHARMACEUTICALS, INC. (US) 1997-09-30 — — US disclosed
EP-0673435-A4 — — 1995-10-25 — — EP disclosed
EP-0673435-A1 SYNTHETIC UNRANDOMIZATION OF OLIGOMER FRAGMENTS ISIS PHARMACEUTICALS, INC. (US) 1995-09-27 — — EP disclosed
WO-1994021825-A1 COMBINATORIAL OLIGOMER IMMUNOABSORBANT SCREENING ASSAY FOR TRANSCRIPTION FACTORS AND OTHER BIOMOLECULE BINDING ISIS PHARMACEUTICALS, INC. (US) 1994-09-29 — — WO disclosed
WO-1993005182-A1 DETERMINATION OF OLIGONUCLEOTIDES FOR THERAPEUTICS, DIAGNOSTICS AND RESEARCH REAGENTS ISIS PHARMACEUTICALS, INC. (US) 1993-03-18 — — WO disclosed
WO-1993004204-A1 SYNTHETIC UNRANDOMIZATION OF OLIGOMER FRAGMENTS ISIS PHARMACEUTICALS, INC. (US) 1993-03-04 — — WO disclosed